Nasdaq:LONA
LeonaBio, Inc.
A clinical-stage biotech firm targeting rare diseases with a focus on advancing innovative therapeutic platforms from discovery to late-stage development.
Key Metrics
Investment Thesis
Bull Case
Investors might buy LONA if they believe in its proprietary platform's ability to successfully transition candidates into clinical trials and secure orphan drug exclusivity; the company maintains a healthy balance sheet relative to its stage with $48.4M cash against only $13.9M in total liabilities, providing runway for further asset advancement.
Bear Case
The stock is risky due to zero revenue history, a massive retained earnings deficit of -$406.1M, and a negative operating profit of -$100.9M that suggests high burn rates; with capital expenditures only at $33,000 against significant cash flow outflows of -$54.8M from investing, the company relies entirely on future financing events or partnership deals to survive.
About LeonaBio, Inc.
LeonaBio, Inc. (NASDAQ: LONA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, leveraging its proprietary platform to advance preclinical candidates into clinical trials.
Analysis
Management Discussion
Management continues to invest heavily in research and development with $70.7M spent in 2024, resulting in a net loss of $96.9M and a year-over-year cash burn that left the company with $48.4M in remaining cash; despite non-cash adjustments totaling $10.0M, the operating cash flow turned negative at -$97.2M, indicating that current assets of $54.8M are insufficient to sustain operations without immediate external funding.
Industry Overview
The rare disease biotechnology industry offers substantial potential for blockbuster orphan drug approvals but is characterized by long development cycles, high failure rates, and a critical dependence on continuous capital infusion; companies in this sector often operate at a loss until product launch, making cash reserves the primary determinant of survival.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $104.0M | $125.5M | $100.9M |
| Operating Income | $-104.0M | $-125.5M | $-100.9M |
| R&D | $61.5M | $93.8M | $70.7M |
| G&A | $32.6M | $33.3M | $26.1M |
| Stock-Based Comp | $10.6M | $10.6M | $11.0M |
| Depreciation | $845.0K | $969.0K | $970.0K |
| Other OpEx | $10.0M | $-1.6M | $4.1M |
| Non-Operating Income | $8.2M | $8.0M | $4.0M |
| Pre-Tax Income | $-95.8M | $-117.4M | $-96.9M |
| Income Tax | $-139.0K | $232.0K | $30.0K |
| Continuing Ops | $-95.6M | $-117.7M | $-96.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-95.6M | $-117.7M | $-96.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-95.6M | $-117.7M | $-96.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $207.5M | $154.7M | $54.8M |
| Cash & Equivalents | $96.0M | $90.6M | $48.4M |
| Marketable Securities | $104.4M | $56.8M | $2.8M |
| Prepaid Expenses | $6.0M | $5.7M | $3.6M |
| Other Current Assets | $1.2M | $1.6M | $0 |
| Long-Term Assets | $50.6M | $5.5M | $3.9M |
| PP&E (Net) | $4.1M | $3.4M | $2.4M |
| Operating Leases | $1.3M | $1.0M | $808.0K |
| LT Investments | $44.8M | — | — |
| Other LT Assets | $475.0K | $1.1M | $686.0K |
| Total Assets | $258.2M | $160.2M | $58.8M |
| Current Liabilities | $21.4M | $28.8M | $13.1M |
| Accounts Payable | $2.5M | $129.0K | $319.0K |
| Current Leases | $326.0K | $368.0K | $414.0K |
| Other Current Liab | $10.0M | $10.0M | $0 |
| Long-Term Liabilities | $1.6M | $1.2M | $803.0K |
| LT Operating Leases | $1.6M | $1.2M | $803.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $23.0M | $30.1M | $13.9M |
| Shareholders' Equity | $235.1M | $130.2M | $44.8M |
| Retained Earnings | $-191.5M | $-309.2M | $-406.1M |
| AOCI | $-2.0M | $-349.0K | $1.0K |
| Total L&E | $258.2M | $160.2M | $58.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-95.6M | $-117.7M | $-96.9M |
| Non-Cash Adjustments | $19.8M | $8.1M | $10.0M |
| Working Capital Changes | $3.3M | $8.8M | $-10.3M |
| Cash from Operations | $-72.5M | $-100.8M | $-97.2M |
| Capital Expenditures | $1.1M | $304.0K | $33.0K |
| Cash from Investing | $57.7M | $95.1M | $54.8M |
| Cash from Financing | $654.0K | $493.0K | $194.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-14.2M | $-5.2M | $-42.1M |
| Beginning Cash | $110.5M | $96.4M | $91.2M |
| Ending Cash | $96.4M | $91.2M | $49.1M |
Frequently Asked Questions
How does LeonaBio, Inc. make money?
The company's financials reflect a single-stage business model typical of early biotechnology firms, where R&D spend ($70.7M) and share-based compensation ($11.0M) are the primary cost drivers while revenue remains at zero as assets are advanced through preclinical or early clinical phases.
What are the main risks for LONA?
The company faces high financial risk due to its significant accumulated deficit of $406.1M and lack of current revenue, creating an urgent need for additional capital; ongoing clinical trial failures could halt development pipelines entirely; regulatory hurdles in the rare disease space remain uncertain; and dilution from equity financing will likely continue given the cash burn rate.
What is LONA's competitive advantage?
LeonaBio possesses a specialized proprietary technology platform tailored for rare disease indications, a highly qualified scientific team with deep expertise in orphan drug development, and strategic partnerships that may provide future commercialization pathways once candidates reach later stages.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.